Kolon Life Science (XKRX:102940) Total Stockholders Equity : ₩159,690 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Kolon Life Science Total Stockholders Equity?

Kolon Life Science's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩159,690 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Kolon Life Science's Book Value per Share for the quarter that ended in Mar. 2024 was ₩13,992.68. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Kolon Life Science's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.77.

Kolon Life Science Total Stockholders Equity Historical Data

The historical data trend for Kolon Life Science's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon Life Science Total Stockholders Equity Chart

Kolon Life Science Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

101,020.43

57,957.13

99,410.16

167,723.25

137,671.98

Kolon Life Science Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															166,063.19	161,643.64	150,652.36	137,671.98	159,690.05

Kolon Life Science (XKRX:102940) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Kolon Life Science's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(159690.047	-	0)	/	11.4124
	=	13,992.68

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Kolon Life Science's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(113290.895	+	10221.604)	/	159690.047
	=	0.77

Kolon Life Science Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Kolon Life Science's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kolon Life Science (XKRX:102940) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kolon Life Science Inc (XKRX:102940) » Definitions » Total Stockholders Equity

Traded in Other Exchanges

N/A

Address

110, Magokdong-ro, Gangseo-gu, One & Only Tower, Seoul, KOR

Website

http://www.kolonls.co.kr

Kolon Life Science Inc develops, manufactures and sells Biopharmaceuticals, Active pharmaceutical ingredients, Antimicrobials and Water solutions. Its products include Invossa, KLS-1010, KLS-2020, Azilsartan, Besfloc etc. The company has manufacturing facilities in Chungju, Eumsung and Kimchun.

Kolon Life Science (XKRX:102940) Headlines

No Headlines